Clinical trials: Flu
Influenza
Trial to Assess Safety, Tolerability, and Immunogenicity of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold-Adapted (FluMist) and Measles, Mumps, Rubella, and Varicella Vaccines Administered Concurrently to Healthy Children
To compare immune responses to measles, mumps, rubella, and varicella antigens following vaccination in children who receive FluMist concurrently with MMRIIÒ and VARIVAXÒ and in children who receive an intranasal placebo mist…
- Trial name
- NCT00192491
- Testing
- FluMist
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Influenza
Multi-Year Study of Fluzone High-Dose Influenza Vaccine Compared With Fluzone® Vaccine in Adults Aged 65 Years and Older
The aim of this study is to determine the efficacy of Fluzone High Dose vaccine and that of Fluzone® vaccine in the elderly. Primary objective: To measure the efficacy of the vaccine, defined as the prevention of…
- Trial name
- NCT00976027
- Testing
- Trivalent inactivated influenza vaccine High Dose, Trivalent inactivated influenza vaccine
- Where
- 98 sites in United States, Puerto Rico
- Volunteers
- 9,172 people, healthy volunteers welcome
- Sponsor
- Sanofi
Influenza
Immunogenicity & Safety of GSK's Avian Flu Vaccine 1557484A Given to Adults Aged ≥18 Years
The purpose of this study is to determine whether GSK's avian flu vaccine GSK 1557484A is immunogenic and safe when given to adults aged >=18 years.
- Trial name
- NCT00719043
- Testing
- A/turkey H5N1 vaccine, Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia)
- Where
- 13 sites in United States, Canada
- Volunteers
- 841 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza, Human
A Study to Evaluate the Immunogenicity and Safety of bioCSL Quadrivalent Influenza Vaccine (QIV) in Adults Aged 18 Years and Above.
This is a study to assess the immune (antibody) response and safety of a bioCSL split virion, inactivated quadrivalent influenza vaccine, in comparison with a US licensed 2014/2015 trivalent influenza vaccine (bioCSL TIV-1), and…
- Trial name
- NCT02214225
- Testing
- Quadrivalent Influenza Vaccine (QIV), Trivalent Influenza Vaccine (TIV-1), Trivalent Influenza Vaccine (TIV-2)
- Where
- 33 sites in United States
- Volunteers
- 3,484 people, healthy volunteers welcome
- Sponsor
- Seqirus
Respiratory Syncytial Virus (RSV)
RSV-F Vaccine and Influenza Vaccine Co-Administration Study in the Elderly
Up to 220 eligible subjects will be enrolled into one of five treatment groups. It is anticipated that some of the randomized study subjects may not complete the study; subjects who withdraw or are discontinued, will not be…
- Trial name
- NCT01709019
- Testing
- Low dose RSV-F Vaccine with Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28), Low dose RSV-F Vaccine without Adjuvant (Day 0); Seasonal TIV (Day 0 & day 28), High dose RSV-F Vaccine with Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28)
- Where
- 4 sites in United States
- Volunteers
- 220 people, healthy volunteers welcome
- Sponsor
- Novavax
Virus Diseases, RNA Virus Infections
Immunogenicity, Safety, and Tolerability of a Plant-Derived Quadrivalent VLP Influenza Vaccine in Elderly Adults
This Phase 2 Quadrivalent VLP Vaccine study is intended to replicate and extend the immunogenicity and safety results obtained in earlier Phase 1-2 and Phase 2 studies.
- Conditions
- Virus Diseases, RNA Virus Infections, Respiratory Tract Diseases, Respiratory Tract Infections
- Trial name
- NCT02831751
- Testing
- 30 µg/strain of Quadrivalent VLP Vaccine, 60 µg/strain of Quadrivalent VLP Vaccine, FluLaval® Tetra (15 µg/strain)
- Where
- 15 sites in United States, Canada
- Volunteers
- 1,001 people, healthy volunteers welcome
- Sponsor
- Medicago
Influenza A
A Study of MHAA4549A as Monotherapy for Acute Uncomplicated Seasonal Influenza A in Otherwise Healthy Adults
This is a Phase 2, randomized, double-blind, placebo-controlled single dose study in otherwise healthy adults with acute uncomplicated seasonal influenza A to assess the safety and tolerability, efficacy, and pharmacokinetics of…
- Trial name
- NCT02623322
- Testing
- MHAA4549A
- Where
- 80 sites in United States, Canada and 5 more
- Volunteers
- 124 people
- Sponsor
- Genentech, Inc.
Influenza
A Re-licensing Study to Assess the Efficacy of Inflexal V Formulated With WHO Recommended 2009/2010 Influenza Virus Strains for the Northern Hemisphere
This study is to assess whether the Northern Hemisphere 2009/2010 season influenza vaccine Inflexal V fulfills the EMEA requirements for re-registration of influenza vaccines.
- Trial name
- NCT01306253
- Testing
- Inflexal V
- Where
- Switzerland
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- Crucell Holland BV
Orthomyxoviridae Infection, Influenza
Lot-to-Lot Consistency Study of the Investigational, Inactivated, Split-Virion Influenza Vaccine in Adults
The primary objective of this trial is to demonstrate the equivalence, in terms of immunogenicity, of three different industrial lots of the investigational vaccine thereby supporting consistency of the manufacturing process.
- Conditions
- Orthomyxoviridae Infection, Influenza, Myxovirus Infection
- Trial name
- NCT00383539
- Testing
- Inactivated Split-virion influenza vaccine
- Where
- 4 sites in France, Lithuania and 2 more
- Volunteers
- 2,256 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza
Trial to Evaluate the Efficacy and Safety of Nitazoxanide in the Treatment of Acute Uncomplicated Influenza
Trial to evaluate efficacy and safety of nitazoxanide (NTZ) in the treatment of acute uncomplicated influenza.
- Trial name
- NCT02612922
- Testing
- Nitazoxanide
- Where
- 28 sites in United States, Australia and 1 more
- Volunteers
- 325 people
- Sponsor
- Romark Laboratories L.C.
Influenza
Safety and Immunogenicity of 2 Commercially Available Influenza Vaccines in Children
This is a study of the safety and immunogenicity of three commercially available influenza vaccines in children.
- Trial name
- NCT00408395
- Testing
- Influenza vaccine
- Where
- Finland
- Volunteers
- 281 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Influenza
A Trial to Assess the Immunogenicity and Safety of the Trivalent Virosomal Influenza Vaccine, Formulation of 2012-2013, in Non-Elderly Adults and Elderly Subjects
This is an open study of the use of AdimFlu-V (2012-2013 season) vaccine in non-elderly and elderly subjects. All participates will receive one dose of vaccine (0.5 ml) by intramuscular injection into the upper arm.
- Trial name
- NCT01759654
- Testing
- AdimFlu-V
- Where
- Taiwan
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Adimmune Corporation
Influenza
Immunogenicity and Safety of Influenza Virus Vaccine, AdimFlu-S (A/H1N1), in Adults and Elders
This was a randomized, laboratory-blinded study in healthy male and non-pregnant female designed to investigate the safety, reactogenicity, and immunogenicity of an inactivated influenza H1N1 vaccine (AdimFlu-S).
- Trial name
- NCT01003145
- Testing
- Influenza A (H1N1) 2009 monovalent vaccine, inactivated
- Where
- 3 sites in Taiwan
- Volunteers
- 292 people, healthy volunteers welcome
- Sponsor
- Adimmune Corporation
COVID-19
A Study of Booster Immunization With COVID-19 Vaccine,Inactivated Co -Administration With Influenza Vaccine and Pneumococcal Polysaccharide Vaccine
This study is a single center , randomized ,controlled and open-label phase Ⅳclinical trial of the booster immunization with the third dose of inactivated COVID-19 vaccine(CoronaVac)manufactured by Sinovac Research \& Development…
- Trial name
- NCT05499351
- Testing
- Adult group in immunogenicity and safety study of combined immunization, Elderly group in immunogenicity and safety study of combined immunization, Adult group in safety observation study of combined immunization
- Where
- China
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Influenza
Reverse Genetic H9N2 Influenza Vaccine Study in Adults
The purpose of the study is to identify the optimal dose level of a reverse genetic (RG) reassortant H9N2 pandemic influenza vaccine for further product development.
- Trial name
- NCT01320696
- Testing
- Reverse Genetic (RG) reassortant A/H9N2 influenza vaccine
- Where
- 5 sites in United States
- Volunteers
- 353 people, healthy volunteers welcome
- Sponsor
- Alachua Government Services, Inc.
SARS-CoV-2 Infection, Influenza A
Clinical Validation of an At-Home Flu A/B and COVID-19 Rapid Test
The study's primary objective is to evaluate the performance of the CorDx Tyfast Flu A/B \& COVID-19 At-Home Test for detecting SARS-CoV-2, Influenza A, and B in nasal samples collected by lay users, compared to 510(k)-cleared…
- Conditions
- SARS-CoV-2 Infection, Influenza A, Influenza B
- Trial name
- NCT07430410
- Testing
- CorDx Tyfast Flu A/B & COVID-19 At-Home Multiplex Rapid Test
- Volunteers
- 200 people
- Sponsor
- CorDx, Inc.
Influenza
Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 Months to 17 Years of Age
The objectives of this study were: To describe the safety of each dosage of high-dose quadrivalent influenza vaccine (QIV-HD) used in the study during the 28 days following each vaccination, and serious adverse events (including…
- Trial name
- QHD04 (NCT03698279)
- Testing
- High-Dose Quadrivalent Influenza Vaccine (QIV-HD) 30 μg (split-virion, inactivated), High-Dose Quadrivalent Influenza Vaccine (QIV-HD) 45 μg, (split-virion, inactivated), High-Dose Quadrivalent Influenza Vaccine (QIV-HD) 60 µg (split-virion, inactivated)
- Where
- 16 sites in United States, Canada
- Volunteers
- 665 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza A
Preliminary Study on Safety and Immunogenicity of Influenza A (H7N9) Vaccine in the Population
Adopt the design of random, blind method and placebo to parallel control and progressive methods of groups to study and evaluate the safety and immunogenicity of influenza A (H7N9) vaccine (two types, one type with two…
- Trial name
- NCT03196661
- Testing
- Influenza A (H7N9) virus vaccine
- Volunteers
- 588 people, healthy volunteers welcome
- Sponsor
- Hualan Biological Bacterin Co. Ltd.
Influenza, Human
Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of QIVc in Subjects ≥2 to <18 Years of Age
This Phase 3/4, randomized, observer-blind, multi-center study, stratified study evaluated the immune (antibody) response, efficacy and safety of a cell-derived quadrivalent subunit influenza virus vaccine (Seqirus QIVc) in…
- Trial name
- NCT03165617
- Testing
- QIVc, Non-influenza Comparator Vaccine
- Where
- 40 sites in Australia, Estonia and 6 more
- Volunteers
- 4,514 people, healthy volunteers welcome
- Sponsor
- Seqirus
Influenza, Orthomyxoviridae Infections
Immunogenicity of the Inactivated Split-Virion Influenza Vaccine in Renal Transplant Subjects
Primary Objective: To describe the immunogenicity of an injection of the investigational inactivated, split-virion influenza vaccine 21 days after vaccination in 18 to 60 years old renal transplant subjects identified as…
- Trial name
- NCT00606359
- Testing
- Inactivated, split-virion influenza virus
- Where
- France
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company